Chen Y, et al. - In Chinese patients with type 2 diabetes mellitus (T2DM) and hyperlipidemia or mixed dyslipidemia, researchers assessed the safety and effectiveness of evolocumab with background atorvastatin. In this pre-specified analysis of patients in the BERSON study in China, patients were initiated with atorvastatin 20 mg/day background and then randomized 2:2:1:1 to evolocumab 140 mg every 2 weeks (Q2W) or 420 monthly (QM) or QM or Q2W placebo. Evolocumab significantly reduced LDL cholesterol and other atherogenic lipids in patients with T2DM and hyperlipidemia or mixed dyslipidemia getting background atorvastatin, was well tolerated, and had no substantial effect on glycemic measures. Over time, there were no differences in glycemic control measures between evolocumab and placebo.